27 results on '"Saluja, Bhawana"'
Search Results
2. Correction to: Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?
3. Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?
4. Sensitivity of Pharmacokinetics to Differences in the Particle Size Distribution for Formulations of Locally Acting Mometasone Furoate Suspension-Based Nasal Sprays
5. Development of an Aerosol Dose Collection Apparatus for In Vitro Dissolution Measurements of Orally Inhaled Drug Products
6. Effects of Formulation Variables on Lung Dosimetry of Albuterol Sulfate Suspension and Beclomethasone Dipropionate Solution Metered Dose Inhalers
7. In Vitro Assessment of Nasal Insufflation of Comminuted Drug Products Designed as Abuse Deterrent Using the Vertical Diffusion Cell
8. Predicting Pulmonary Pharmacokinetics from In Vitro Properties of Dry Powder Inhalers
9. Bioequivalence for Orally Inhaled and Nasal Drug Products
10. Scientific Considerations for the Review and Approval of First Generic Mometasone Furoate Nasal Suspension Spray in the United States from the Bioequivalence Perspective
11. Influence of Formulation Factors on the Aerosol Performance of Suspension and Solution Metered Dose Inhalers: A Systematic Approach
12. Novel low molecular weight lignins as potential anti-emphysema agents: In vitro triple inhibitory activity against elastase, oxidation and inflammation
13. Regulatory Considerations for Approval of Generic Inhalation Drug Products in the US, EU, Brazil, China, and India
14. Effect of Device Design and Formulation on the In Vitro Comparability for Multi-Unit Dose Dry Powder Inhalers
15. The Influence of Secondary Processing on the Structural Relaxation Dynamics of Fluticasone Propionate
16. Systematic Evaluation of the Effect of Formulation Variables on In Vitro Performance of Mometasone Furoate Suspension-Metered Dose Inhalers
17. Correction to: Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?
18. Sulfated Caffeic Acid Dehydropolymer Attenuates Elastase and Cigarette Smoke Extract-induced Emphysema in Rats: Sustained Activity and a Need of Pulmonary Delivery
19. Bioequivalence for Orally Inhaled and Nasal Drug Products
20. Immunomodulatory Therapeutic Proteins in COVID‐19: Current Clinical Development and Clinical Pharmacology Considerations
21. Clinical Pharmacology Considerations for Developing Small‐Molecule Treatments for COVID‐19
22. A Comprehensive Updated Review on SARS‐CoV‐2 and COVID‐19
23. Drug Interaction Between Febuxostat and Thiopurine Antimetabolites: A Review of the FDA Adverse Event Reporting System and Medical Literature
24. Patient Focus and Regulatory Considerations for Inhalation Device Design: Report from the 2015 IPAC-RS/ISAM Workshop
25. <italic>In Vitro</italic> Assessment of Nasal Insufflation of Comminuted Drug Products Designed as Abuse Deterrent Using the Vertical Diffusion Cell.
26. NOVEL CINNAMIC ACID-BASED DEHYDROPOLYMERS FOR EMPHYSEMA: IN VITRO AND IN VIVO ASSESSMENT OF THEIR ACTIVITIES
27. The Influence of Secondary Processing on the Structural Relaxation Dynamics of Fluticasone Propionate
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.